Astellas Gets Europe Okay For AML Drug Xospata

Pulls Further Ahead Of Daiichi Sankyo's Rival FLT3 Inhibitor

Following green lights in the US and Japan, Xospata has been approved for relapsed or refractory FLT3-positive acute myeloid leukemia. Getting first-line approval is the next step.

Check list
Astellas ticks off a third major approval for Xospata • Source: Shutterstock

Astellas Pharma Inc. has consolidated its lead over fellow Japanese rival Daiichi Sankyo Co. Ltd. in the acute myeloid leukemia field following the approval of its FLT3 inhibitor Xospata by the European Commission.

The approval comes after the European Medicines Agency's drug evaluation committee, the CHMP, issued a positive opinion for Xospata (gilteritinib)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category